1. Fleischer AB Jr, Parrish CA, Glenn R, Feldman SR. Condylomata acuminata (genital warts): patient demographics and treating physicians. Sex Transm Dis. 2001;28(11):643-7. [
DOI:10.1097/00007435-200111000-00006] [
PMID]
2. Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16,and 18) vaccine. J Infect Dis. 2009;199(6):805-14. [
DOI:10.1086/597071] [
PMID]
3. Oriel JD. Natural history of genital warts. Br J Vener Dis. 1971;47(1):1-13. [
DOI:10.1136/sti.47.1.1] [
PMID] [
PMCID]
4. Padel AF, Venning VA, Evans MF, Quantrill AM, Fleming KA. Human papillomaviruses in anogenital warts in children: typing by in situ hybridisation. BMJ. 1990;300(6738):1491-4. [
DOI:10.1136/bmj.300.6738.1491] [
PMID] [
PMCID]
5. Gissmann L, Wolnik L, Ikenberg H, Koldovsky U, Schnurch HG, zur Hausen H. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc Natl Acad Sci U S A. 1983;80(2):560-3. [
DOI:10.1073/pnas.80.2.560] [
PMID] [
PMCID]
6. Stanley M. Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer. Br J Cancer. 2007;96(9):1320-3. [
DOI:10.1038/sj.bjc.6603695] [
PMID] [
PMCID]
7. Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol Oncol. 2010;117(2 Suppl):S5-10. [
DOI:10.1016/j.ygyno.2010.01.024] [
PMID]
8. Centers for Disease Control and Prevention (CDC) . Sexually Transmitted Diseases Treatment Guidelines. Morb Mortal Wkly Rep. 2010;59:69-74.
9. Kodner CM, Nasraty S. Management of genital warts. Am Fam Physician. 2004;70(12):2335-42.
10. Forcier M, Musacchio N. An overview of human papillomavirus infection for the dermatologist: disease, diagnosis, management, and prevention. Dermatol Ther. 2010;23(5):458-76. [
DOI:10.1111/j.1529-8019.2010.01350.x] [
PMID]
11. Osborne NG, Adelson MD. Herpes simplex and human papillomavirus genital infections: controversy over obstetric management. Clin Obstet Gynecol. 1990;33(4):801-11. [
DOI:10.1097/00003081-199012000-00014] [
PMID]
12. Workowski KA, Bolan GA, Centers for Disease C. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1-137.
13. Mant C, Cason J, Rice P, Best JM. Non-sexual transmission of cervical cancer-associated papillomaviruses: an update. Papillomavirus Rep. 2000;11(1):1-5.
14. Ferenczy A. HPV-associated lesions in pregnancy and their clinical implications. Clin Obstet Gynecol. 1989;32(1):191-9. [
DOI:10.1097/00003081-198903000-00023] [
PMID]
15. Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis: a review. Laryngoscope. 2008;118(7):1236-47. [
DOI:10.1097/MLG.0b013e31816a7135] [
PMID]
16. Khan F, Mays R, Brooks J. Viral and sexually transmitted disease. In: Kroumpouzos G, editor. Text Atlas of Obstetric Dermatology. Philadelphia: Lippincott Williams & Wilkins; 2013. pp. 126-40.
17. Zuo Z, Goel S, Carter JE. Association of cervical cytology and HPV DNA status during pregnancy with placental abnormalities and preterm birth. Am J Clin Pathol. 2011;136(2):260-5. [
DOI:10.1309/AJCP93JMIUEKRPIW] [
PMID]
18. MacMahan E, Fox E, Lockwood D. Gynecologic dermatology. In: Black M, Ambros-Rudolph C, Edwards E, editors. Obstetric and Gynecologic Dermatology. St. Louis: Mosby; 2008. pp. 107-19.
19. Bonnez W, Elswick RK Jr, Bailey-Farchione A, Hallahan D, Bell R, Isenberg R, et al. Efficacy and safety of 0.5% podofilox solution in the treatment and suppression of anogenital warts. Am J Med. 1994;96(5):420-5. [
DOI:10.1016/0002-9343(94)90168-6]
20. Tyring SK, Arany I, Stanley MA, Tomai MA, Miller RL, Smith MH, et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis. 1998;178(2):551-5. [
DOI:10.1086/517472] [
PMID]
21. Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas JM Jr. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol. 1998;38(2 Pt 1):230-9. [
DOI:10.1016/S0190-9622(98)70243-9]
22. Lacey CJN. Genital warts and mucosal papillomavirus disease. Medicine. 2014;42(7):349-53. [
DOI:10.1016/j.mpmed.2014.04.012]
23. Lacey CJ, Woodhall SC, Wikstrom A, Ross J. 2012 European guideine for the management of anogenital warts. J Eur Acad Dermatol Venereol. 2013;27(3):e263-70. [
DOI:10.1111/j.1468-3083.2012.04493.x] [
PMID]
24. Ciavattini A, Tsiroglou D, Vichi M, Di Giuseppe J, Cecchi S, Tranquilli AL. Topical Imiquimod 5% cream therapy for external anogenital warts in pregnant women: report of four cases and review of the literature. J Matern Fetal Neonatal Med. 2012;25(7):873-6. [
DOI:10.3109/14767058.2011.600795] [
PMID]
25. Condylomata International Collaborative Study Group . Recurrent condylomata acuminata treated with recombinant interferon alpha2a. A multicenter double-blind placebo-controlled clinical trial. Condylomata International Collaborative Study Group. Acta Derm Venereol. 1993;73(3):223-6.
26. Reid R, Greenberg MD, Pizzuti DJ, Omoto KH, Rutledge LH, Soo W. Superficial laser vulvectomy. V. Surgical debulking is enhanced by adjuvant systemic interferon. Am J Obstet Gynecol. 1992;166(3):815-20. [
DOI:10.1016/0002-9378(92)91339-C]
27. Petersen CS, Bjerring P, Larsen J, Blaakaer J, Hagdrup H, From E, et al. Systemic interferon alpha-2b increases the cure rate in laser treated patients with multiple persistent genital warts: a placebo-controlled study. Genitourin Med. 1991;67(2):99-102. [
DOI:10.1136/sti.67.2.99] [
PMID] [
PMCID]
28. Fleshner PR, Freilich MI. Adjuvant interferon for anal condyloma. A prospective, randomized trial. Dis Colon Rectum. 1994;37(12):1255-9. [
DOI:10.1007/BF02257792] [
PMID]
29. Armstrong DK, Maw RD, Dinsmore WW, Blaakaer J, Correa MA, Falk L, et al. Combined therapy trial with interferon alpha-2a and ablative therapy in the treatment of anogenital warts. Genitourin Med. 1996;72(2):103-7. [
DOI:10.1136/sti.72.2.103] [
PMID] [
PMCID]
30. Douglas JJ, Eron LJ, Judson FN, Rogers M, Alder MB, Taylor E, et al. A randomized trial of combination therapy with intralesional interferon alpha 2b and podophyllin versus podophyllin alone for the therapy of anogenital warts. J Infect Dis. 1990;162(1):52-9. [
DOI:10.1093/infdis/162.1.52] [
PMID]
31. Armstrong DK, Maw RD, Dinsmore WW, Morrison GD, Pattman RS, Watson PG, et al. A randomised, double-blind, parallel group study to compare subcutaneous interferon alpha-2a plus podophyllin with placebo plus podophyllin in the treatment of primary condylomata acuminata. Genitourin Med. 1994;70(6):389-93. [
DOI:10.1136/sti.70.6.389] [
PMID] [
PMCID]
32. Handley JM, Horner T, Maw RD, Lawther H, Dinsmore WW. Subcuta neous interferon alpha 2a combined with cryotherapy vs cryotherapy alone in the treatment of primary anogenital warts: a randomised ob server blind placebo controlled study. Genitourin Med. 1991;67(4):297-302. [
DOI:10.1136/sti.67.4.297] [
PMID] [
PMCID]
33. Bleeker MC, Hogewoning CJ, Voorhorst FJ, van den Brule AJ, Snijders PJ, Starink TM, et al. Condom use promotes regression of human papillomavirus-associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia. Int J Cancer. 2003;107(5):804-10. [
DOI:10.1002/ijc.11473] [
PMID]